Sweden’s Super Company 2018
(2018-10-16) UmanDiagnostics has been awarded the prestigious nomination Super Company 2018 by the business magazine Veckans Affärer together with Bisnode. Growth and profitability for four years in a row are some of the essential criteria assessed for qualifying on the list. Super Companies accounts for 0.16% of the total number of limited companies in Sweden and is a great proof of UmanDiagnostics business strategy.
Meet us at ECTRIMS Berlin
(2018-09-06) UmanDiagnostics will attend this year ECTRIMS conference in Berlin (October 10-12th). Please visit us at booth no. D06.
UmanDiagnostics recieves ISO13485:2016 certification
(2018-07-06) UmanDiagnostics has today been quality certified according to ISO13485:2016 further strengthening the company commitment to delivering first class products to it’s valued world wide customers.
UmanDiagnostics and Quanterix improving brain injury diagnostics
(2016-11-21) UmanDiagnostics has today entered into a strategic partnership with Quanterix™, a Boston based company digitizing biomarker analysis for precision health. The aim is to further develop UmanDiagnostics NF-light® ELISA to enable blood analysis of traumatic brain injuries and neurodegenerative diseases. Combining superior antibodies with the most sensitive technology has the possibility to transform neurological diagnostics.
UmanDiagnostics starts selling reagents
(2016-10-07) Due to the great interest in using our antibodies on ultra sensitive platforms we are very happy to announce that we now will be able to deliver antibodies and antigen for Neurofilament light detection. Please use our contact form if you need more information.
UmanDiagnostics nominated for award